Literature DB >> 26576738

Novel sodium channel antagonists in the treatment of neuropathic pain.

Mirko Rivara1, Valentina Zuliani1.   

Abstract

INTRODUCTION: Effective and safe drugs for the treatment of neuropathic pain are still an unmet clinical need. Neuropathic pain, caused by a lesion or disease that affects the somatosensory system, is a debilitating and hampering condition that has a great economic cost and, above all, a tremendous impact on the quality of life. Sodium channels are one of the major players in generating and propagating action potentials. They represent an appealing target for researchers involved in the development of new and safer drugs useful in the treatment of neuropathic pain. The actual goal for researchers is to target sodium channels selectively to stop the abnormal signaling that characterizes neuropathic pain while leaving normal somatosensory functions intact. AREAS COVERED: This review covers the most recent publications regarding sodium channel blockers and their development as new treatments for neuropathic pain. The main areas discussed are the natural sources of new blockers, such as venom extracts and the recent efforts from many pharmaceutical companies in the field. EXPERT OPINION: There have been serious efforts by both the pharmaceutical industry and academia to develop new and safer therapeutic options for neuropathic pain. A number of different strategies have been undertaken; the main efforts directed towards the identification of selective blockers starting from both natural products or screening chemical libraries. At this time, researchers have identified and characterized selective compounds against NaV1.7 or NaV1.8 voltage-gated sodium channels but only time will tell if they reach the market.

Entities:  

Keywords:  Neuropathic pain; pain; sodium channel blockers; sodium channel isoforms

Mesh:

Substances:

Year:  2015        PMID: 26576738     DOI: 10.1517/13543784.2016.1121992

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  8 in total

1.  Sodium Channel Blockers.

Authors:  Benjamin Blass
Journal:  ACS Med Chem Lett       Date:  2017-02-23       Impact factor: 4.345

2.  Bicyclic Ketone Sulfonamide Compounds.

Authors:  Benjamin Blass
Journal:  ACS Med Chem Lett       Date:  2017-02-23       Impact factor: 4.345

Review 3.  Combining Human and Rodent Genetics to Identify New Analgesics.

Authors:  Alban Latremoliere; Michael Costigan
Journal:  Neurosci Bull       Date:  2017-07-01       Impact factor: 5.203

4.  Chitosan Oligosaccharide Reduces Propofol Requirements and Propofol-Related Side Effects.

Authors:  Zhiwen Li; Xige Yang; Xuesong Song; Haichun Ma; Ping Zhang
Journal:  Mar Drugs       Date:  2016-12-21       Impact factor: 5.118

5.  NaV channel variants in patients with painful and nonpainful peripheral neuropathy.

Authors:  Samir Wadhawan; Saumya Pant; Ryan Golhar; Stefan Kirov; John Thompson; Leslie Jacobsen; Irfan Qureshi; Senda Ajroud-Driss; Roy Freeman; David M Simpson; A Gordon Smith; Ahmet Hoke; Linda J Bristow
Journal:  Neurol Genet       Date:  2017-12-15

Review 6.  Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain.

Authors:  Hong Xiao; Ke Ma; Dong Huang; Xian-Guo Liu; Tang-Hua Liu; Qing Liu; Guang-Zhao Liu; Tao Song; Wei Tao; Da-Sheng Wu; Yun-Xia Wang; Xiao-Qiu Yang; Xiao-Mei Zhang; Hui Liu; Yan-Qing Liu
Journal:  World J Clin Cases       Date:  2021-03-26       Impact factor: 1.337

7.  Centipede Venom Peptides Acting on Ion Channels.

Authors:  YanYan Chu; PeiJu Qiu; RiLei Yu
Journal:  Toxins (Basel)       Date:  2020-04-05       Impact factor: 4.546

Review 8.  Understanding the genetic basis of congenital insensitivity to pain.

Authors:  Ichrak Drissi; William Aidan Woods; Christopher Geoffrey Woods
Journal:  Br Med Bull       Date:  2020-05-15       Impact factor: 4.291

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.